NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Europe Cell & Gene Therapy Manufacturing Market — Growth Drivers, Restraints and Future Outlook 2032

Europe Cell & Gene Therapy Manufacturing Market valued at USD 1.8B (2023), projected USD 5.6B by 2032 at 13.5% CAGR with rising clinical trials and regulatory.

Revenue, 2023

$1.8B

Forecast, 2032

$5.6B

CAGR, 2024-2032

13.5%

Report Coverage

North America

Code: europe-cell-gene-therapy-manufacturing-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The Europe Cell & Gene Therapy Manufacturing Market was valued at USD 1.8 billion in 2023 and is projected to reach USD 5.6 billion by 2032, growing at a 13.5% CAGR. Europe accounts for approximately 32% of the global cell and gene therapy manufacturing market, driven by a robust clinical pipeline, favorable regulatory pathways via the EMA, and significant investments by pharmaceutical companies in advanced manufacturing infrastructure. Germany and the United Kingdom lead regional adoption. Key players include Lonza, Oxford Biomedica, and Miltenyi Biotec. The market presents substantial investment opportunities in viral vector manufacturing, autologous cell therapy scaling, and decentralized manufacturing models, though high production costs and supply chain complexity remain notable constraints.

02

Key Highlights

1

Europe accounts for 32% of the global cell and gene therapy manufacturing market with a 13.5% CAGR through 2032.

2

Germany and the UK lead European adoption driven by strong pharma presence and supportive regulatory frameworks.

3

Contract manufacturing segment dominates at 60% market share as biotech firms outsource production to CDMOs.

03

Market Overview

Market Context

Europe's cell and gene therapy manufacturing sector is rapidly expanding, driven by over 200 active clinical trials, EMA regulatory support, and significant CDMO investments in advanced manufacturing platforms across the region.

Europe's cell and gene therapy manufacturing market is experiencing rapid expansion, supported by over 200 ongoing clinical trials and strong regulatory support from the EMA. The region hosts major CDMOs and biotech firms investing in next-generation manufacturing platforms. Rising approvals of CAR-T therapies and AAV-based gene therapies are key growth catalysts.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Increasing CDMO partnerships with biotech firms for viral vector manufacturingShift toward allogeneic cell therapies to reduce cost per doseAdoption of single-use bioreactor systems across European manufacturing facilitiesGrowing integration of AI and digital twins in bioprocess optimization
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 13.5%

Base Year (2023)

$1.8B

Forecast (2032)

$5.6B

CAGR (2024-2032)

13.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$1.80B
2024$2.04B
2025$2.32B
2026$2.63B
2027$2.99B
2028$3.39B
2029$3.85B
2030$4.37B
2031$4.96B
2032$5.63B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The market is projected to grow from USD 1.8 billion in 2023 to USD 5.6 billion by 2032 at a 13.5% CAGR, fueled by rising CAR-T approvals, expanding AAV gene therapy pipelines, and increasing CDMO outsourcing demand.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America40.0%12.8%United States
Europe32.0%13.5%Germany
Asia Pacific28.0%15.2%China

North America

#1
Share: 40.0%CAGR: 12.8%

Largest market: United States

Europe

#2
Share: 32.0%CAGR: 13.5%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising clinical pipeline of cell and gene therapies in Europe
  • Supportive EMA regulatory frameworks and accelerated approvals
  • Increased pharma investment in advanced manufacturing infrastructure
06

Market Segmentation

By Service Type
Market share distribution across 2 segments
By Service Type — market share by segment, in percent.
SegmentShare
Contract ManufacturingCDMO-provided manufacturing services for pharma and biotech companies.60.0%
In-House ManufacturingPharma companies manufacturing therapies through owned facilities.40.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Therapy Type
Market share distribution across 2 segments
By Therapy Type — market share by segment, in percent.
SegmentShare
Cell Therapy ManufacturingIncludes autologous and allogeneic cell therapy production such as CAR-T, CAR-NK, and stem cell therapies.55.0%
Gene Therapy ManufacturingCovers viral vector-based gene therapies including AAV, lentiviral, and adenoviral vector production.45.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic and Research Institutes
  • Hospitals and Clinics
07

Regional Analysis

1

North America

Lead: United States
CAGR: 12.8%Share: 40.0%

Largest market driven by FDA approvals, strong biotech ecosystem, and significant CDMO presence.

2

Europe

Lead: Germany
CAGR: 13.5%Share: 32.0%

Fast-growing market supported by EMA regulatory pathways, strong pharma presence, and rising clinical trials.

3

Asia Pacific

Lead: China
CAGR: 15.2%Share: 28.0%

Emerging high-growth region driven by cost-effective manufacturing and increasing government investment.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
35.0%
+12.5%
Germany
14.0%
+14.2%
China
12.0%
+18.5%
08

Competitive Landscape

L

Lonza

Switzerland

LeaderCHF 7.2B

Global CDMO leader with major European operations, offering end-to-end cell and gene therapy manufacturing services including viral vector and CAR-T production.

Switzerland-based global CDMO leader and largest contract manufacturer of cell and gene therapies with extensive European manufacturing footprint.

T

Thermo Fisher Scientific

United States

Challenger

Provides comprehensive gene and cell therapy manufacturing solutions through its Brammer Bio and PPD subsidiaries with expanding European footprint.

O

Oxford Biomedica

United Kingdom

FollowerGBP 185M

UK-based specialist in gene and cell therapy contract development and manufacturing, with strong expertise in lentiviral and AAV vector production.

UK-based gene and cell therapy CDMO specializing in lentiviral and AAV vector manufacturing for clinical and commercial supply.

Also profiled

M

Miltenyi Biotec

EUR 750M

Germany-based biotechnology company providing cell therapy manufacturing tools, reagents, and GMP-compliant processing solutions.

09

Recent Developments

25
2025Lonza

Expanded viral vector manufacturing capacity at its Visp facility to meet growing AAV and lentiviral demand.

24
2024Oxford Biomedica

Signed a major gene therapy CDMO agreement with a top-10 pharma company for commercial-scale AAV production.

10

Regulatory Landscape

EMA Advanced Therapy Medicinal Products (ATMP) Regulation (EC) No 1394/2007EU GMP Annex 2 for Advanced Therapy Medicinal ProductsEU Cell and Tissue-Based Products Directive 2004/23/EC
11

Research Methodology

Primary research

  • Expert interviews with CDMO executives
  • Surveys of biotech and pharma manufacturing decision-makers

Secondary research

  • Industry analyst reports
  • Company financial filings and press releases

Validation: Triangulation method

12

Strategic Takeaways

Investors

The 13.5% CAGR presents strong growth potential in viral vector and allogeneic cell therapy manufacturing segments.

Operators

Investing in single-use platforms and AI-driven bioprocess optimization will be critical for competitive differentiation.

Strategists

Early partnerships with emerging biotech firms and expansion into decentralized manufacturing models offer key growth avenues.

Regulators

Harmonizing cross-border GMP standards across EU member states remains essential for market efficiency.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.